Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0

Ian Law, Nathalie L Albert, Javier Arbizu, Ronald Boellaard, Alexander Drzezga, Norbert Galldiks, Christian la Fougère, Karl-Josef Langen, Egesta Lopci, Val Lowe, Jonathan McConathy, Harald H Quick, Bernhard Sattler, David M Schuster, Jörg-Christian Tonn, Michael Weller

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

These joint practice guidelines, or procedure standards, were developed collaboratively by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neurooncology (EANO), and the working group for Response Assessment in Neurooncology with PET (PET-RANO). Brain PET imaging is being increasingly used to supplement MRI in the clinical management of glioma. The aim of these standards/guidelines is to assist nuclear medicine practitioners in recommending, performing, interpreting and reporting the results of brain PET imaging in patients with glioma to achieve a high-quality imaging standard for PET using FDG and the radiolabelled amino acids MET, FET and FDOPA. This will help promote the appropriate use of PET imaging and contribute to evidence-based medicine that may improve the diagnostic impact of this technique in neurooncological practice. The present document replaces a former version of the guidelines published in 2006 (Vander Borght et al. Eur J Nucl Med Mol Imaging. 33:1374-80, 2006), and supplements a recent evidence-based recommendation by the PET-RANO working group and EANO on the clinical use of PET imaging in patients with glioma (Albert et al. Neuro Oncol. 18:1199-208, 2016). The information provided should be taken in the context of local conditions and regulations.

Original languageEnglish
Pages (from-to)540-557
Number of pages18
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume46
Issue number3
DOIs
Publication statusPublished - 1 Mar 2019

Cite this

Law, Ian ; Albert, Nathalie L ; Arbizu, Javier ; Boellaard, Ronald ; Drzezga, Alexander ; Galldiks, Norbert ; la Fougère, Christian ; Langen, Karl-Josef ; Lopci, Egesta ; Lowe, Val ; McConathy, Jonathan ; Quick, Harald H ; Sattler, Bernhard ; Schuster, David M ; Tonn, Jörg-Christian ; Weller, Michael. / Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG : version 1.0. In: European Journal of Nuclear Medicine and Molecular Imaging. 2019 ; Vol. 46, No. 3. pp. 540-557.
@article{343b0d2e467844ac9c7f35adc90b3f61,
title = "Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0",
abstract = "These joint practice guidelines, or procedure standards, were developed collaboratively by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neurooncology (EANO), and the working group for Response Assessment in Neurooncology with PET (PET-RANO). Brain PET imaging is being increasingly used to supplement MRI in the clinical management of glioma. The aim of these standards/guidelines is to assist nuclear medicine practitioners in recommending, performing, interpreting and reporting the results of brain PET imaging in patients with glioma to achieve a high-quality imaging standard for PET using FDG and the radiolabelled amino acids MET, FET and FDOPA. This will help promote the appropriate use of PET imaging and contribute to evidence-based medicine that may improve the diagnostic impact of this technique in neurooncological practice. The present document replaces a former version of the guidelines published in 2006 (Vander Borght et al. Eur J Nucl Med Mol Imaging. 33:1374-80, 2006), and supplements a recent evidence-based recommendation by the PET-RANO working group and EANO on the clinical use of PET imaging in patients with glioma (Albert et al. Neuro Oncol. 18:1199-208, 2016). The information provided should be taken in the context of local conditions and regulations.",
keywords = "FDG, FDOPA, FET, Glioma, MET, PET",
author = "Ian Law and Albert, {Nathalie L} and Javier Arbizu and Ronald Boellaard and Alexander Drzezga and Norbert Galldiks and {la Foug{\`e}re}, Christian and Karl-Josef Langen and Egesta Lopci and Val Lowe and Jonathan McConathy and Quick, {Harald H} and Bernhard Sattler and Schuster, {David M} and J{\"o}rg-Christian Tonn and Michael Weller",
year = "2019",
month = "3",
day = "1",
doi = "10.1007/s00259-018-4207-9",
language = "English",
volume = "46",
pages = "540--557",
journal = "European Journal of Nuclear Medicine and Molecular Imaging",
issn = "1619-7070",
publisher = "Springer Verlag",
number = "3",

}

Law, I, Albert, NL, Arbizu, J, Boellaard, R, Drzezga, A, Galldiks, N, la Fougère, C, Langen, K-J, Lopci, E, Lowe, V, McConathy, J, Quick, HH, Sattler, B, Schuster, DM, Tonn, J-C & Weller, M 2019, 'Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0' European Journal of Nuclear Medicine and Molecular Imaging, vol. 46, no. 3, pp. 540-557. https://doi.org/10.1007/s00259-018-4207-9

Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG : version 1.0. / Law, Ian; Albert, Nathalie L; Arbizu, Javier; Boellaard, Ronald; Drzezga, Alexander; Galldiks, Norbert; la Fougère, Christian; Langen, Karl-Josef; Lopci, Egesta; Lowe, Val; McConathy, Jonathan; Quick, Harald H; Sattler, Bernhard; Schuster, David M; Tonn, Jörg-Christian; Weller, Michael.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 46, No. 3, 01.03.2019, p. 540-557.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG

T2 - version 1.0

AU - Law, Ian

AU - Albert, Nathalie L

AU - Arbizu, Javier

AU - Boellaard, Ronald

AU - Drzezga, Alexander

AU - Galldiks, Norbert

AU - la Fougère, Christian

AU - Langen, Karl-Josef

AU - Lopci, Egesta

AU - Lowe, Val

AU - McConathy, Jonathan

AU - Quick, Harald H

AU - Sattler, Bernhard

AU - Schuster, David M

AU - Tonn, Jörg-Christian

AU - Weller, Michael

PY - 2019/3/1

Y1 - 2019/3/1

N2 - These joint practice guidelines, or procedure standards, were developed collaboratively by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neurooncology (EANO), and the working group for Response Assessment in Neurooncology with PET (PET-RANO). Brain PET imaging is being increasingly used to supplement MRI in the clinical management of glioma. The aim of these standards/guidelines is to assist nuclear medicine practitioners in recommending, performing, interpreting and reporting the results of brain PET imaging in patients with glioma to achieve a high-quality imaging standard for PET using FDG and the radiolabelled amino acids MET, FET and FDOPA. This will help promote the appropriate use of PET imaging and contribute to evidence-based medicine that may improve the diagnostic impact of this technique in neurooncological practice. The present document replaces a former version of the guidelines published in 2006 (Vander Borght et al. Eur J Nucl Med Mol Imaging. 33:1374-80, 2006), and supplements a recent evidence-based recommendation by the PET-RANO working group and EANO on the clinical use of PET imaging in patients with glioma (Albert et al. Neuro Oncol. 18:1199-208, 2016). The information provided should be taken in the context of local conditions and regulations.

AB - These joint practice guidelines, or procedure standards, were developed collaboratively by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neurooncology (EANO), and the working group for Response Assessment in Neurooncology with PET (PET-RANO). Brain PET imaging is being increasingly used to supplement MRI in the clinical management of glioma. The aim of these standards/guidelines is to assist nuclear medicine practitioners in recommending, performing, interpreting and reporting the results of brain PET imaging in patients with glioma to achieve a high-quality imaging standard for PET using FDG and the radiolabelled amino acids MET, FET and FDOPA. This will help promote the appropriate use of PET imaging and contribute to evidence-based medicine that may improve the diagnostic impact of this technique in neurooncological practice. The present document replaces a former version of the guidelines published in 2006 (Vander Borght et al. Eur J Nucl Med Mol Imaging. 33:1374-80, 2006), and supplements a recent evidence-based recommendation by the PET-RANO working group and EANO on the clinical use of PET imaging in patients with glioma (Albert et al. Neuro Oncol. 18:1199-208, 2016). The information provided should be taken in the context of local conditions and regulations.

KW - FDG

KW - FDOPA

KW - FET

KW - Glioma

KW - MET

KW - PET

UR - http://www.scopus.com/inward/record.url?scp=85058002482&partnerID=8YFLogxK

U2 - 10.1007/s00259-018-4207-9

DO - 10.1007/s00259-018-4207-9

M3 - Article

VL - 46

SP - 540

EP - 557

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

IS - 3

ER -